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Abstract
IMPORTANCE Observational studies have shown associations of birth weight with type 2 diabetes
(T2D) and glycemic traits, but it remains unclear whether these associations represent causal
associations.
OBJECTIVE To test the association of birth weight with T2D and glycemic traits using a mendelian
randomization analysis.
DESIGN, SETTING, AND PARTICIPANTS This mendelian randomization study used a genetic risk
score for birth weight that was constructed with 7 genome-wide significant single-nucleotide
polymorphisms. The associations of this score with birth weight and T2Dwere tested in a mendelian
randomization analysis using study-level data. The association of birth weight with T2Dwas tested
using both study-level data (7 single-nucleotide polymorphisms were used as an instrumental
variable) and summary-level data from the consortia (43 single-nucleotide polymorphismswere used
as an instrumental variable). Data from 180056 participants from 49 studies were included.
MAINOUTCOMESANDMEASURES Type 2 diabetes and glycemic traits.
RESULTS This mendelian randomization analysis included 49 studies with 41 155 patients with T2D
and 80008 control participants from study-level data and 34 840 patients with T2D and 114 981
control participants from summary-level data. Study-level data showed that a 1-SD decrease in birth
weight due to the genetic risk score was associated with higher risk of T2D among all participants
(odds ratio [OR], 2.10; 95% CI, 1.69-2.61; P = 4.03 × 10−5), among European participants (OR, 1.96;
95% CI, 1.42-2.71; P = .04), and among East Asian participants (OR, 1.39; 95% CI, 1.18-1.62; P = .04).
Similar results were observed from summary-level analyses. In addition, each 1-SD lower birth weight
was associated with 0.189 SD higher fasting glucose concentration (β = 0.189; SE = 0.060;
P = .002), but not with fasting insulin, 2-hour glucose, or hemoglobin A1c concentration.
CONCLUSIONS ANDRELEVANCE In this study, a genetic predisposition to lower birth weight was
associated with increased risk of T2D and higher fasting glucose concentration, suggesting genetic
effects on retarded fetal growth and increased diabetes risk that either are independent of each
other or operate through alterations of integrated biological mechanisms.
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Introduction
Type 2 diabetes (T2D) has become a worldwide epidemic, with more than 422million patients in
2014.1 However, the etiology of T2D is not fully understood. Identifying potentially causal risk factors
would help guide prevention of the disease.
Key Points
Question Is birth weight associated
with type 2 diabetes and glycemic traits?
Findings Thismendelian randomization
study found that a 1-SD decrease in birth
weight due to the genetic risk scorewas
associated with a higher risk of type 2
diabetes among European and East
Asian populations. In addition, a 1-SD
decrease in birth weight was associated
with a 0.189-SD increase in fasting
glucose concentration, but not with
fasting insulin, 2-hour glucose, or
hemoglobin A1c level.
Meaning A genetic predisposition to
lower birth weight was associated with
an increased risk of type 2 diabetes and
increased fasting glucose, suggesting
potential mechanisms through which
perturbation of the antenatal and early-
life environment affect predisposition
to diabetes in later life.
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The thrifty phenotype hypothesis postulates that fetal growth and nutrition play important
roles in influencing susceptibility to T2D in later life.2 In observational studies, low birth weight, a
widely used indicator for fetal growth restriction, has been consistently associated with higher risk of
T2D3,4 and adverse glycemic traits5 in later life. However, both maternal socioeconomic status and
unmeasured lifestyle factors might confound these associations; therefore, the causality of these
observations remains to be determined. We hypothesized that birth weight may be causally
associated with T2D risk and related traits such as fasting glucose concentration, insulin level, insulin
resistance, and insulin sensitivity.
Mendelian randomization (MR) analysis has becomewidely used to assess the potential causal
associations of environmental risk factors with disease.6-11 This method is analogous to a randomized
clinical trial where randomization to genotype takes place at conception, and it is less likely to be
affected by confounding and reverse causation.7,12 Previous analyses have provided compelling
evidence that fetal genotype has substantial impact on early growth, as measured by birth weight.13
Therefore, in this study, we used the genetic variants for birth weight as an instrumental
variable14,15 to perform anMR analysis to examine the association of birth weight with T2D and
glycemic traits, using both study-level data and summary-level data.
Methods
StudyDesign
This study was conducted using summary association data generated by previous studies. Owing to
the use of previously collected, deidentified, aggregated data, this study did not require institutional
review board approval per the US Federal Policy for Protection of Human Research Subjects. Ethical
approval was obtained for all original studies. Reporting of this study followed the Strengthening the
Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.
Observational studies are prone to reverse causation, confounding, and biases and can generate
unreliable findings in relation to the causal effects of modifiable exposures on disease outcomes.
Mendelian randomization is a method aimed at unbiased detection of causal effects and estimation
of their magnitudes (eMethods in the Supplement). To consistently estimate the causal effects, the
genetic variants used in an MR analysis must satisfy 3 assumptions (eFigure 1 in the Supplement):16
(1) the genetic variants used as instrumental variables (IV) are associated with the exposure (birth
weight); (2) the genetic variants are not associated with any confounder of the exposure-outcome
association; and (3) the genetic variants are conditionally independent of the outcome (T2D and
glycemic traits) given the exposure and confounders. The second and third assumptions are known
as independence from pleiotropy.16
The study design of this MR analysis consisted of 2 components17-23 (Figure 1). First, we
explored the association of birth weight with risk of T2D using study-level data, including 49 cross-
sectional and prospective cohort studies with a total of 180056 participants, including 41 155
patients with T2D from the Cohorts for Heart and Aging Research in Genomic Epidemiology—Birth
Gene Study (CHARGE-BIG). The primary IV was a genetic risk score (GRS) for birth weight using 7
single-nucleotide polymorphisms (SNPs) (P < 5 × 10−8) from a genome-wide association study
(GWAS) in the Early Growth Genetics (EGG) Consortium.23 We analyzed the data within each study
using standardized analytic methods. The IV estimator is calculated as the pooled β coefficient from
the GRS-T2D association divided by the pooled β coefficient from the GRS–birthweight association.
Second, we tested the association of birth weight with T2D and glycemic traits using summary-level
data from the EGG Consortium (n = 153 781),13,23 the Diabetes Genetics Replication and Meta-
analysis (DIAGRAM) Consortium (n = 149821),17 and the Meta-analyses of Glucose and Insulin-
Related Traits (MAGIC) Consortium (n = 133010).18-22 In this study, the 7-SNP score23 was used as the
main IV because the new GWAS that identified 60 SNPs for birth weight was published after the
study-level results had already been run. Therefore, we used the 43 SNPs available in this analysis, a
subset of the 60 SNPs,13 as the IV for birth weight in summary-level analyses.
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Study Populations andData Sources
Study-Level Data
Study-level data including 49 cross-sectional and prospective cohort studies with up to 180056
participants from the CHARGE-BIG were used (eTable 1 in the Supplement). Descriptions of each
participating study are shown in the eAppendix in the Supplement. All participants provided written,
informed consent, and ethical approval was granted by local ethics committees for participating
studies (eTable 2 in the Supplement). Birth weight was collected by self-reported questionnaires or
medical records in each study. Detailed information on the study-specific data collection methods is
provided in eTable 2 in the Supplement. Covariates were measured using direct measurement or
self-reported using questionnaire data from each study (eTable 2 in the Supplement). The primary
outcomes were prevalence or incidence of T2D, defined based on report of T2D or current use of
antidiabetes medication. Participants with missing values or those lost to follow-up were excluded.
Precise information on the outcome for each study is reported in eTable 3 in the Supplement.
Selection of SNPs andGRS Calculation
Seven SNPs were identified as being associated with birth weight by a previous GWAS.23 All studies
used direct genotype information on SNPs for birth weight from previously genotyped array data.
Whenever a SNP was not genotyped directly, we used either (1) the HapMap II CEU (European)
reference panel-imputed genetic information from GWAS or (2) genotype information from a
predefined list of proxies that are in high linkage disequilibriumwith the SNP (r2 > 0.8). Genotyping
platforms, genotype frequencies, Hardy-Weinberg equilibrium P values, and call rates for the 7 SNPs
are listed in eTable 4 and eTable 5 in the Supplement. To estimate the genetic predisposition to low
birth weight, a GRS for low birth weight was calculated on the basis of these 7 well-established SNPs
(eTable 6 in the Supplement).23 We assumed that each SNP in the panel acts independently in an
additive manner, and the GRS was calculated using a weightedmethod (eAppendix in the
Supplement).
Summary-Level Data
Summary-level data from the EGG Consortium,13,23 DIAGRAM Consortium,17 andMAGIC
Consortium18-22 were used. For IV, both the 7-SNP GRS (explained between 0.32% and 1.52% of
variance in birth weight) (eTable 6 and eTable 7 in the Supplement)23 and the 43-SNP GRS (explained
2.0% of variance in birth weight) (eTable 8 and eTable 9 in the Supplement)13 for birth weight were
Figure 1. Study Design
Instrumental variables
• Genetic risk score of 7 SNPs for birth weighta
• Genetic risk score of 43 SNPs for birth weightb
Primary outcome
Disease: type 2 diabetes
Secondary outcomes
Glycemic traits: fasting glucose, fasting
insulin, 2-h glucose, and HbA1c
156 869 CHARGE-BIG of 48 studies
149 821 DIAGRAM Consortium
156 869 CHARGE-BIG of 48 studies
69 308 EGG Consortiuma
153 781 EGG Consortiumb
133 010 MAGIC Consortium
Sources of data for analysis included study-level data from the Cohorts for Heart and
Aging Research in Genomic Epidemiology Birth Gene (CHARGE-BIG) Study (49 studies,
n = 180056 participants) and summary-level data from the Diabetes Genetics
Replication andMeta-analysis (DIAGRAM) Consortium (n = 149821 participants),17 the
Meta-analyses of Glucose and Insulin-Related Traits (MAGIC) Consortium (n = 133010
participants),18-22 and the Early Growth Genetics (EGG) Consortium (n = 153 781
participants).13,23 HbA1c indicates hemoglobin A1c; and SNP, single-nucleotide
polymorphism.
a Estimates of 7 SNPs for birth weight were extracted from the EGG Consortium
(n = 69 308 participants).23
b Estimates of 43 SNPs for birth weight were extracted from the EGG Consortium
(n = 153 781 participants).13
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used from 2 previous GWAS studies in the EGG Consortiumwith up to 153 781 individuals. For T2D,
data were obtained from the DIAGRAM Consortium; this study included 149821 individuals of
European descent.17 In addition to the primary outcomes of T2D, secondary outcomes of glycemic
traits such as fasting glucose, fasting insulin, 2-hour glucose, and hemoglobin A1c concentrations
were examined (eTable 7 and eTable 9 in the Supplement). Data from theMAGIC Consortiumwith up
to 133010 individuals were used for glycemic traits. Informed consent was obtained from all
participants of contributing studies. Contributing studies received ethical approval from their
respective institutional review boards.
Statistical Analysis
Study-Level Data
For study-level data from the CHARGE-BIG study, a standard analytic protocol was applied to each
individual study to produce comparable results. Logistic regression was used to test the association
of birth weight with risk of T2D after adjustment for age, sex, and other baseline covariates, where
available (smoking status, physical activity, total energy intake, and alcohol intake). Linear regression
was used to test the association of the GRS with birth weight after adjustment for age, sex, and
principal components for population stratification (principal components analysis [PCA]). Logistic
regression was used to test the association of the GRS with risk of T2D after adjustment for age, sex,
and PCA. The inclusion of PCA as covariates is commonly used to correct for population stratification
according to ancestral background.24
To validate assumption 1, that the GRS for birth weight was a strong IV for birth weight
(eTable 10 in the Supplement), an F statistic for the IV was calculated in the Nurses’ Health Study
(NHS) andHealth Professionals Follow-up Study (HPFS) cohorts as ameasure of the strength of IV for
prediction of the birth weight, controlling for covariates (age, sex, PCA). An F statistic greater than
10 is evidence of a strong IV.25
To examine assumption 2, that GRS for birth weight was not associated with potential
confounders, the association of the GRS with age, bodymass index, smoking, alcohol use, and total
energy intake was determined among individuals in the NHS and HPFS cohorts (eTable 11 in the
Supplement).
Meta-analyses were conducted using study-level data from each study; we then pooled the β
coefficients across studies, using random-effects or fixed-effects meta-analysis. Meta-analyses were
conducted in Stata statistical software version 13.0 (StataCorp). All P values reported are 2-sided.We
assessed heterogeneity with the I2 statistic. We assessed between-study heterogeneity via the
CochraneQ statistic and I2 statistics.26-28 For the proposed cutoff of I2 > 0.25, we found
nonnegligible heterogeneity between studies, in particular among the birth weight–T2D associations,
but also for the association between GRS and birth weight or T2D (I2 > 0.25). As a consequence, we
used random-effects meta-analysis throughout. After meta-analysis, we used the IV estimators to
quantify the strength of the association of birth weight with risk of T2D.29 The IV estimator, which is
identical to that derived by the widely used 2-stage least-squares method,30 was calculated as the
β of the regression coefficients for GRS-T2D and GRS–birth weight associations (eMethods in the
Supplement).
Summary-Level Data
For the summary-level data from the EGG, DIAGRAM, andMAGIC consortia, the estimates of the
association of birth weight with T2D risk and glycemic traits were pooled using the inverse-variance
weighted, MR-Egger, and weighted-median methods for multiple genetic variants (eMethods in the
Supplement). Detailed information on this MRmethod has been described previously.31-33
To examine assumption 3, that the IV for birth weight affects risk of T2D only through birth
weight, but not through other pathways, the MR-Egger method was used (eMethods in the
Supplement). Egger regression is a tool to detect small study bias in meta-analysis and it can be
adapted to test for bias from type I pleiotropy, which is problematic for the interpretation ofMR. Type
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I pleiotropy occurs when a single locus directly influences multiple phenotypes and is more
pronounced at the level of the gene than at the level of single SNPs.6 Under the assumption that the
association of each genetic variant with the exposure is independent of the pleiotropic effect of the
variant (not via the exposure), the MR-Egger test gives a valid test of the null causal hypothesis.16
Using theMR-Egger method, the effect of the IV on the exposure is plotted against its effect on the
outcome, and an intercept distinct from the origin provides evidence for pleiotropic effects.
Additionally, the slope of the MR-Egger can provide pleiotropy-corrected causal estimates under a
weaker assumption (the instrument strength independent of direct effect assumption).16
For analyses of both study-level data and summary-level data, the effect size for each meta-
analysis is reported in themain results as the effect of a 1-SD change in birth weight or glycemic
quantitative traits, as this metric is more interpretable than an arbitrary difference. Absolute risk
increase (ARI) per 1000 participant-years for T2Dwas also calculated (eMethods in the Supplement).
P < .05 was considered statistically significant. Analyses were performed using Stata statistical
software version 13 (StataCorp) and R statistical software version 3.2.3 (R Project for Statistical
Computing).
Results
Characteristics of the 49Participating Studies
The characteristics of the 49 participating studies with up to 180056 participants, including 41 155
patients with T2D, are presented in eTable 1 in the Supplement. Twenty-two studies reported the
genetic association between GRS and birth weight, and 33 studies reported the genetic association
between GRS and risk of T2D. A total of 41 155 patients with T2D and 80008 control individuals
without T2D provided study-level data. Data from the DIAGRAM Consortium included 34 840
patients with T2D and 114 981 control individuals, overwhelmingly of European descent.17 The
MAGIC Consortium included 133010 participants,18-22 and the EGG Consortium included 153 781
participants (Figure 1).13,23
Results for TestingMRAssumptions
To validate MR assumptions 1 and 2, the NHS and HPFS cohorts were used to examine the
associations of GRS with birth weight and potential confounders. We found that the GRS for birth
weight was a strong IV (F > 18) (eTable 10 in the Supplement), thus validating assumption 1. In
addition, no associations between the GRS and age, bodymass index, smoking, alcohol use, and total
energy intake were observed in the NHS and HPFS cohorts (eTable 11 in the Supplement), thus
validating assumption 2.
Association of BirthWeightWith Risk of T2D
Study-level data showed that each 1-SD decrease in birth weight due to the GRS was associated with
higher risk of T2D among all participants (odds ratio [OR], 2.10; 95%CI, 1.69-2.61; and ARI per 1000
participant-years, 8.9; 95% CI, 0.2-9.0; P = 4.03 × 10−5), among European participants (OR, 1.96;
95% CI, 1.42-2.71; and ARI per 1000 participant-years, 7.48; 95% CI, 3.27-13.34; P = .04)34 (Table 1),
and among East Asian participants (OR, 1.39; 95% CI, 1.18-1.62; and ARI per 1000 participant-years,
3.04; 95% CI, 1.40-4.84; P = .04) (Figure 2; eFigure 2 and eFigure 3 in the Supplement). We did not
find a significant difference in OR for T2D betweenMR estimates and conventional observational
results (OR, 1.41 per 1-SD lower birth weight; 95% CI, 1.16-1.66) from 11 studies of the CHARGE-BIG
(P = .86) (eFigure 4 in the Supplement).
We further conducted stratified analyses of estimated causality by age, sex, bodymass index,
ethnic group, sample size, study design, and number of SNPs included. An association of birth weight
with T2Dwas observed among bothmen and women, both obese and normal-weight participants,
and both European and East Asian participants. However, evidence for a causal association was not
observed in the subsample of individuals younger than 50 years (Table 2).
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Summary-level data showed a similar association of low birth weight with risk of T2Dwhen
using the 7 SNPs (OR, 2.79; 95% CI, 1.90-4.20; and ARI per 1000 participant-years, 13.96; 95% CI,
7.02-24.96; P = .02) and when using 43 SNPs (OR, 1.86; 95% CI, 1.07-3.60; and ARI per 1000
participant-years, 6.70; 95% CI, 0.55-20.28; P = .03) (Figure 2). We further excluded previously
reported loci for T2D such as CDKAL1, ADCY5, BCAR1, HHEX/IDE, GCK, MTNR1B, and ANK1, and low
birth weight remained associated with risk of T2D (OR, 1.75; 95% CI, 1.05-3.16; P = .04).
Association of BirthWeightWith Glycemic Quantitative Traits
Using the weightedmedian–basedmethod, we found that a 1-SD lower birth weight due to the GRS
was associated with 0.189 SD higher fasting glucose concentration (β = 0.189; SE = 0.060; P = .002)
at the Bonferroni-adjusted level of significance (P < .01). Consistently, the inverse-variance–
weighted analysis also showed an association of birth weight with fasting glucose concentration
Table 1. Mendelian Randomization of BirthWeight and Risk of Type 2 Diabetes
MR Estimatesa
Summary Data Ab Summary Data Bb
OR (95% CI) P Value OR (95% CI) P Value
Simple median–based methodc 1.57(1.24 to 2.00) 2.0 × 10-4 1.24(1.09 to 1.41) .001
Weighted median–based methodc 1.52(1.24 to 1.86) 1.1 × 10-4 1.29(1.13 to 1.47) 6.0 × 10-4
Inverse-variance–weighted methodc 1.69(1.12 to 2.55) .045 1.36(1.14 to 1.62) .001
MR-Egger methodc 2.79(1.90 to 4.20) .02 1.96(1.07 to 3.60) .03
MR-Egger regressiond 0.007 (−0.081 to 0.095) .94 0.011 (−0.002 to 0.02) .22
Abbreviations: MR, mendelian randomization; OR, odds ratio.
a In anMR framework, genetic variants for birth weight were assumed to influence type 2 diabetes only through birth
weight, not through other pathways. In the present study, we usedMR-Egger regression to assess for the presence of
pleiotropy.16 This approach is based on Egger regression, which was used to assess publication bias in the
meta-analysis.34 Using the MR-Egger method, the β coefficient of the MR-Egger regression provides pleiotropy-
corrected causal estimates and an intercept distinct from the origin provides evidence for pleiotropic effects.16
b Sample sizes of patients with type 2 diabetes and control individuals were 12 171 and 56862 for both summary data A and
summary data B. Number of single-nucleotide polymorphisms used of summary data A and summary data B are 7 and
43, respectively. Number of participants with birth weight in summary data A and summary data B are 69 308 and
153 781, respectively.
c We used simple median–basedmethod, weightedmedian–basedmethod, inverse-variance–weightedmethod, and
MR-Egger method to provide consistent results for causal effect of birth weight on type 2 diabetes.
d Values in this row are intercept (95% CI).
Figure 2. Mendelian Randomization of BirthWeight and Risk of Type 2 Diabetes (T2D)
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For type 2 diabetes, the data were analyzed from 49 studies from the Cohorts for Heart
and Aging Research in Genomic Epidemiology Birth Gene Study where standardized
analytic methods were used in individual study. This study included 41 155 patients with
T2D and 80008 controls. Data from the Diabetes Genetics Replication and Meta-
analysis (DIAGRAM) Consortium included 34 840 patients with T2D and 114 981
controls, overwhelmingly of European descent. Summary results of 7 single-nucleotide
polymorphisms (SNPs) for birth weight identified in genome-wide association studies
were extracted from the Early Growth Genetics Consortium.23 Summary results for risk
of T2Dwere extracted from the DIAGRAMConsortium.17 Summary results of 43 SNPs for
birth weight were extracted from the Early Growth Genetics birth weight genome-wide
association study.13 Summary results for risk of T2D were extracted from the DIAGRAM
Consortium.17 We used the standard deviation value (543 g) from the birth weight
genome-wide association study of the EGG Consortium.13 Results are standardized to a
1-SD lower birth weight owing to genetic risk score. ARI indicates absolute risk increase;
OR, odds ratio
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(0.207 SD higher fasting glucose concentration per 1-SD lower birth weight; β = 0.0.207; SE = 0.073;
P = .03) (Table 3). These findings were replicated using the 43 SNPs as an IV, suggesting robustness
of our findings. However, there was no evidence for an association of birth weight with other
glycemic traits such as fasting insulin, 2-hour glucose, or hemoglobin A1c concentrations (Table 3).
Sensitivity Analyses ofMR
In sensitivity analyses, we used 4 different methods (simple median based, weightedmedian based,
inverse-variance weighted, andMR-Egger) to estimate the association of birth weight with risk of
T2D using summary-level data. The results showed consistent associations (Table 2), indicating
robustness of our findings. We further conducted a sensitivity analysis of association of birth weight
with risk of T2D using 8 studies providing both GRS–birth weight and GRS-T2D associations
(eFigure 5 in the Supplement) in the CHARGE-BIG study. Similarly, we found that each 1-SD lower
birth weight due to the GRS was associated with higher risk of T2D (OR, 2.66; 95% CI, 1.30-4.02;
P = 6.76 × 10−4), providing further evidence of finding robustness.
To examineMR assumption 3, we further tested whether any of the selected SNPs were
influenced by linkage disequilibrium and pleiotropy. We found that none of the SNPs were in linkage
disequilibriumwith each other (r2 > 0.05). In addition, the intercept term estimated fromMR-Egger
was centered at the origin with a confidence interval including the null (0.007; 95% CI −0.081 to
0.095; P = .94) (Table 1), suggesting the results were not influenced by pleiotropy. For glycemic
Table 2. Stratified Analyses of Estimated Causality Between BirthWeight and Risk of Type 2 Diabetes
Subgroup
Genetic Association of Birth Weight per SDa Genetic Association of Type 2 Diabetes Estimated Causalityb
No. of
Studies β (95% CI) P Value
No. of
Studies β (95% CI) P Value OR (95% CI) P Value
Age, y 23
≥50
0.04 (0.03 to 0.05) 3.6 × 10−4
28 0.03 (0.01 to 0.05) .0004 2.12 (1.70 to 2.64) .0006
<50 5 0.04 (−0.10 to 0.02) .18 1.67 (0.87 to 5.65) .18
Sex
Male 17 0.04 (0.02 to 0.05) 8.4 × 10−4 24 0.03 (0.01 to 0.05) .006 1.89 (1.46 to 2.46) .02
Female 16 0.04 (0.01 to 0.06) 9.4 × 10−4 23 0.03 (0.01 to 0.04) .002 2.10 (1.49 to 2.97) .03
Body mass indexc 23
≥25
0.04 (0.03 to 0.05) 3.6 × 10−4
25 0.02 (0.00 to 0.04) .02 1.81 (1.39 to 2.37) .03
<25 8 0.04 (0.02 to 0.06) <.001 2.82 (2.20 to 3.60) 3.1 × 10−5
Ethnic group
European 22 0.04 (0.03 to 0.05) 3.6 × 10−4 24 0.03 (0.01 to 0.05) .02 1.96 (1.42 to 2.71) .04
East Asian 1 0.09 (0.00 to 0.18) 5.1 × 10−3 9 0.03 (0.02 to 0.04) <.001 1.39 (1.18 to 1.62) .04
Sample size, No. 23
≥1500
0.04 (0.03 to 0.05) 3.6 × 10−4
27 0.03 (0.01 to 0.04) .001 1.96 (1.58 to 2.44) .002
<1500 6 0.07 (0.03 to 0.12) <.001 3.45 (2.41 to 6.19) .003
Study design 23
Cohort
0.04 (0.03 to 0.05) 3.6 × 10−4
26 0.03 (0.01 to 0.05) <.001 2.06 (1.64 to 2.60) .002
Case-control 5 0.02 (−0.03 to 0.06) .47 1.55 (0.85 to 2.84) .47
Cross-sectional 2 0.06 (−0.01 to 0.16) .19 3.26 (0.89 to 7.02) .19
No. of
single-nucleotide
polymorphisms
23
7
0.04 (0.03 to 0.05) 3.6 × 10−4
27 0.03 (0.01 to 0.05) .003 2.17 (1.65 to 2.87) .005
<7 6 0.03 (0.01 to 0.04) .0004 1.91 (1.58 to 2.31) .0007
Abbreviation: OR, odds ratio.
a Results were standardized to a 1-SD decrease in birth weight due to genetic risk score.
The standard deviation was 543 g from the Early Growth Genetics Consortium.13
b The estimates were derived from 49 studies from the Cohorts for Heart and Aging
Research in Genomic Epidemiology Birth Gene Study where standardized analytic
methods adjusted for confounders such as age, body mass index, sex, and the first 3
principal components for population stratification were used in individual study. In a
mendelian randomization framework, the association between genetic risk score and
type 2 diabetes is assumed to be independent of confounding factors. In our study, the
instrumental variable estimator is calculated as the β coefficient from the association
of genetic risk score with type 2 diabetes divided by the β coefficient from the
association of genetic risk score with birth weight. These results are supportive of a
causal, nonconfounded association.
c Calculated as weight in kilograms divided by height in meters squared.
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traits, the intercept (SE) fromMR-Egger regression also suggested that the observed results were not
influenced by pleiotropy (Table 3).
Discussion
In the largest MR study thus far, to our knowledge, we investigated a potential causal role of birth
weight in the development of T2D and regulation of glycemic traits using study-level data and
summary-level data. Our results show that genetically determined lower birth weight was associated
with increased risk of T2D and elevated fasting glucose concentration, supporting an association
between lower birth weight and development of T2D.
Compelling observational studies have shown that lower birthweight is associatedwith a higher
T2D risk.3,4,35-40 For example, data from ameta-analysis of 30 studies found an inverse birth
weight–T2D association; the pooled OR of T2Dwas 1.13 (95% CI, 1.10-0.1.17) per kilogram decrease in
birth weight.3 However, in most of the observational studies included in this meta-analysis, birth
weight was associated with potential confounders. Therefore, residual confoundingmay have
contributed to the observed associations, illustrating a major limitation of observational studies in
inference of causality. In the present study, we usedMR analysis to minimize the potential
confounding effect. The GRS used in our study was not correlated with potential confounders, and
was validated as a strong and reliable IV for birth weight.15 Therefore, our findings concur with a
previous study15 and lend genetic support to prior evidence of observational association between
birth weight and risk of T2D.
Table 3. Mendelian Randomization Analyses of BirthWeight and Glycemic Quantitative Traitsa
Data Source SD
No.
MR Estimates, Units of SD per 1-SD Decrease in Birth Weight
MR-Egger Regression
Weighted Median–Based
Method
Inverse-Variance–Weighted
Method MR-Egger Method
SNPs Participants β (SE) P Value β (SE) P Value β (SE) P Value Intercept (SE) P Value
Fasting glucose, mg/dL
Summary data Ab 13.1 7 133 010 0.189 (0.060) .002 0.207 (0.073) .03 0.113 (0.341) .74 0.005 (0.017) .78
Summary data Bc 13.1 43 133 010 0.109 (0.049) .03 0.415 (0.105) .04 0.031 (0.099) .23 −0.018 (0.010) .07
Fasting insulin,
log (pmol/L)
Summary data Ab 0.44 7 108 557 0.089 (0.096) .36 0.021 (0.108) .86 0.131 (0.502) .79 −0.006 (0.026) .82
Summary data Bc 0.44 43 108 557 0.033 (0.082) .69 0.050 (0.060) .41 −0.027
(0.213)
.90 0.002 (0.006) .70
2-h glucose, mg/dLd
Summary data Ab 10.1 7 42 854 0.494 (0.352) .16 0.563 (0.411) .22 −0.584
(1.851)
.75 0.060 (0.094) .52
Summary data Bc 10.1 43 42 854 0.406 (0.254) .11 0.319 (0.203) .12 0.378 (0.727) .60 −0.002 (0.022) .93
Hemoglobin A1c,
% of total hemoglobin
Summary data Ab 0.54 7 46 368 0.118 (0.072) .10 0.186 (0.084) .07 0.135 (0.390) .73 0.003 (0.020) .89
Summary data Bc 0.54 43 46 368 0.038 (0.063) .55 0.086 (0.069) .22 0.158 (0.242) .51 −0.002 (0.007) .76
Abbreviations: HbA1c, hemoglobinA1c; MR, mendelian randomization; SNP, single-
nucleotide polymorphism.
SI conversion factor: To convert glucose tommol/L, multiply by 0.0555; HbA1c to
proportion of total hemoglobin, multiply by 0.01.
a Results were standardized to a 1-SD decrease in birth weight due to genetic variants.
For birth weight, 1-SDwas assumed to correspond to 543 g, the pooled results from the
Early Growth Genetics (EGG) Consortium.23 TheMeta-analyses of Glucose and
Insulin-Related Traits (MAGIC) Consortium did not report estimates of variants in units
of standard deviations. β values from this consortiumwere standardized so that the
association of birth weight with glycemic traits could be uniformly expressed in terms
of standard deviations. For fasting glucose, 2-hour glucose, and HbA1c from the MAGIC
Consortium, 1 SDwas assumed to correspond to 13.1 mg/dL, 10.1 mg/dL, and 0.535%,
respectively, the pooled SD of studies included in a previous report from theMAGIC
Consortium.18 The threshold of significance was at the Bonferroni-adjusted level
P < .01 (0.05 / 4 = 0.01).
b Estimates of 7 SNPs for birth weight were extracted from EGG Consortium.23 For
glycemic traits, estimates were derived from theMAGIC Consortium (n = 133010
participants).18-22
c Estimates of 43 SNPs for birth weight were extracted from EGG Consortium.13 For
glycemic traits, estimates were derived from theMAGIC Consortium (n = 133010
participants).18-22
d Two-hour glucose refers to measured blood glucose concentration 2 hours after
consumption of dissolved glucose.
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Our findings suggest that birth weight may be a useful target for a prevention strategy to
mitigate T2D risk in later life. According to the thrifty phenotype hypothesis,2 the observed
associations may originate in utero where intrauterine growth restriction affects epigenetic
alterations and alters intracellular insulin-signaling pathways.41,42 Such permanent alterations in
structure, physiology, andmetabolism are thought to result in key disruptions to the endocrine
system.42,43 It has been suggested that the public health implications of the inverse birth weight–T2D
association depend on the precise nature of the underlying causal exposure and its amenability to
change.3 OurMR results demonstrate that birth weight itself is a causal exposure, implying the public
health impact of birth weight modification. Interestingly, previous interventions for increasing birth
weight through changes in maternal nutrition have increased birth weight by up to 200 g in
populations.44 Such an increase in birth weight could translate into a reduction in T2D risk of up to
10%.3 Therefore, our findings highlight the potential importance of improving fetal growth and
nutrition in the prevention of T2D. In addition, ongoing research to understand themechanistic links
between the genetic loci that influence birth weight may lead to novel therapeutic strategies to
modify birth weight and subsequently reduce the risk of T2D.45 Importantly, our findings are of
public health significance andmay help in understanding themechanisms by which low birth weight
increases risk of T2D.
TheMR analysis used in this study satisfied 3 assumptions. Assumption 1 requires a strong link
between the genetic variants used as an IV and birth weight. The GRS used in our study was
demonstrated to be a strong IV with an F statistic greater than 18.31 For assumption 2, MR assumes
the IV (GRS) was not associatedwith potential confounders. Study-level results showed that GRSwas
not associated with potential confounders; nevertheless, we could not exclude the possibility that
our resultsmight be affected by unmeasured confounders. For assumption 3,MR assumes that the IV
for birth weight affects risk of T2D only through birth weight, but not through other pathways. To
validate assumption 3,16 the intercept term estimated fromMR-Egger regression was centered at the
origin with a confidence interval including the null, suggesting that our results were not influenced
by pleiotropy.
Our current study has several other strengths. First, to our knowledge, our study is the largest
MR analysis assessing the association of birth weight with T2D risk and glycemic traits to date. The
large sample size allowed us to assess the consistency of associations across studies and to gain
sufficient power for conclusive estimation of associations. Second, sensitivity analyses of 2 different
data sources (study-level and summary-level data sets) were conducted. The steps taken in this
study reduced the risk of bias and pleiotropy. Importantly, the consistent associations estimated from
complementary MR approaches, such as the weighted median regression method, inverse-
variance–weightedmethod, andMR-Egger method, support the robustness of our findings. Finally,
most of the studies includedwere homogeneous, andwe used standardizedmethods and performed
the analysis individually in each study. Therefore, the effect of population stratification on the
instrumental results should beminimal.
Limitations
This study has some limitations, and the results should be interpreted with sufficient caution.
Although theMRmethod is theoretically well established, we recognize that there are still many
limitations in practice. First, we assumed that the associations of birth weight with T2D and glycemic
traits were linear. Indeed, several observational studies suggested U-shaped associations.46-49
Therefore, further investigations employing a nonlinear MR approach are warranted to investigate
the causality. In addition, we only used 7 SNPs in study-level analyses; this may lead to a weak IV, and
thus introduce bias. Second, although theMR-Egger method suggested that our results were not
affected by pleiotropy, it is possible that the shared genetic basis between birth weight and T2Dmay
also contribute to the association. Third, although previous evidence indicated that variation in the
fetal genome was the predominant driver of the birth weight associations,13 birth weight may be
influenced by both fetal and correlatedmaternal genotypes. Given the correlation (r of
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approximately 0.5) betweenmaternal and fetal genotype,13 we could not exclude the possibility that
associations between fetal genotype and birth weight may result from indirect effects of the
maternal genotype influencing birth weight via the intrauterine environment.13 In addition, recent
GWAS identified several novel loci for offspring birth weight and highlightedmaternal genetic effects
that are independent of fetal genetics.50 Therefore, there are limitations in assuming causality on the
basis of fetal genotype and fetal phenotype associations; dissecting maternal and fetal effects on
adult T2D risk are also needed. In addition, maternal genetic variants could influence both offspring
birth weight and other aspects of nurturing. Cross-generation MR studies are susceptible to such
dynamic effects, which introduce potential biases. Therefore, future cross-generationMR studies
should consider ways to reduce the biases that might result from these assumption violations.51
Fourth, the widely used GRSmay not fit the assumptions for an IV well. Furthermore, most of
the risk factors are not static, but dynamic, and this may only be captured by taking both genetic and
environmental factors into account over time. Fifth, assumption 3, that genetic markers affect T2D
only through birth weight, is sometimes referred to as the exclusion restriction. TheMR assumptions
are violated if the genetic marker affects T2D through pathways other than through birth weight,
whichmay lead to substantial biases in MR analysis.52 We cannot exclude the possibility that genetic
markers for birthweight were associatedwith other pathways that influence T2D risk. In the present
study, we used only the MR-Egger method to examine assumption 3. Although we found that the
results were not influenced by pleiotropy, the MR-Egger analysis has limitations and is not able to
reliably detect a dose-response relationship in the genetic associations with birth weight and with
T2D, and hence cannot distinguish between pleiotropy and causal effect.53 Sixth, even thoughmany
relevant covariates, including age, sex, ethnicity, region, total energy, and PCAwere included in the
statistical models, residual and unmeasured confounding cannot be ruled out. Many established
confounders, such as maternal diet, lifestyle, and additional genetic markers, may confound the
association of birth weight with T2D risk. Further investigation considering these confounders is
needed. In addition, given that the studies involved are overwhelmingly in non-Hispanic white
populations, testing for generalizability to other ethnic groups warrants further investigation.
Conclusions
This study found that genetic predisposition to lower birth weight was associated with increased risk
of T2D and impaired fasting glucose concentration. Our results suggest the presence of genetic
effects on retarded fetal growth and increased diabetes risk that either are independent of each
other or operate through alterations of integrated biological mechanisms.
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